David Polidori

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Julio Rosenstock, Naresh Aggarwal, David Polidori et al. · Diabetes Care · 2012 · 420 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Sue Sha, Damayanthi Devineni, A. Ghosh et al. · Diabetes Obesity and Metabolism · 2011 · 294 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Robert R. Henry, Payal Thakkar, Cindy S.W. Tong et al. · Diabetes Care · 2015 · 288 citations

Medicine, Pharmacology, Pharmacotherapy +17

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

John P. Bilezikian, Nelson B. Watts, Keith Usiskin et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 266 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion

David Polidori, Sue Sha, Sunder Mudaliar et al. · Diabetes Care · 2013 · 263 citations · Full text

Medicine, Endocrinology, Pharmacology +17